UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2012
PURAMED BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
|
Minnesota
|
00-52771
|
20-5510104
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
1326 Schofield Avenue
Schofield, WI 54476
(Address of principal executive offices)
(715) 359-6373
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Effective January 09, 2012, the board of directors of PuraMed BioScience, Inc (the “company”) appointed Sue Baacke as the new Chief Financial Officer of the Company replacing James Higgins who maintains his role as the Company’s Chief Operating Officer.
Sue Baacke is a Certified Public Accountant and has been the Company’s Corporate Controller since April 2009. Prior to working at the Company, Sue worked at Koenig & Lundin, S.C., a Certified Public Accounting firm for over twelve years and attained experience in: auditing, preparation and review of financial statements, individual, corporate, and partnership income tax returns, payroll, and valuation of closely-held businesses.
|
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PURAMED BIOSCIENCE, INC.
|
|||
|
January 10, 2012
|
By:
|
/s/ Russell W. Mitchell
|
|
|
Name: Russell W. Mitchell
|
|||
|
Title: Chief Executive Officer
|
|||
|
|
|||